Surprisingly, however, Zhang and colleagues found in 2008 that serum FGF21 was significantly increased in obese patients and associated with increased risk of the metabolic syndrome, suggesting FGF21 as potential biomarker for metabolic diseases (17). The gene discussed is FGF21; the disease is metabolic disease.